An evaluation of cannabidiol on sleep and how this relates to epileptic electroencephalogram abnormalities and seizures in adults with Lennox-Gastaut Syndrome and Dravet Syndrome

Alfred Health0 个研究点目标入组 26 人开始时间: 2023年8月8日最近更新: 2023年8月21日

适应症

试验速览

暂无简介。

•Participants will be eligible to be included in the study if all the following criteria apply:
•Aged 18 to 60 years;
•Diagnosis of Dravet syndrome or Lennox-Gastaut syndrome and prescribed, but have not yet commenced EPIDYOLEX as part of their routine clinical care by their neurologist;
•Stable epilepsy treatment (pharmacotherapy treatment, ketogenic diet, vagal nerve stimulation or deep brain stimulation) for at least 4 weeks prior to treatment initiation; and
•Written informed consent obtained from the participant prior to any study-related procedures.

•Participants are excluded from the study if any of the following criteria apply:
•Current treatment with cannabis-based products;
•Unstable hepatic or renal disease;
•Epilepsy surgery, or vagal nerve stimulation/deep brain stimulation implantation in the past 6-months; or
•Patients treated with continuous positive airway pressure (CPAP) .

发起方